Asian Journal of Biomedical and Pharmaceutical Sciences

Journal Banner

Study of Imatinib Mesylate Treated Patients sufferening from Chronic Myeloid Leukemia

Chronic Myeloid Leukemia (CML) is also an attractive target for a rationally designed drug development programme and it was probably the first form of leukemia to be recognized as a distinct entity. In our present follow up study, taken normal healthy individuals, Interferon alpha, Hydroxyurea, Imatinib mesylate treated patient. The percentage response rate of interferon was 90% in which 10% have shown complete response, 30% with partial response and 50% with stable condition. The response rates in patients treated with Imatinib mesylate have shown 87.5%. The overall major cytogenetic response (MCR) was 2.5%, Complete cytogenetic response (CCR) was 77.5% and 7.5% in stable condition. This clearly demonstrates that Indian patients respond to this drug better than their foreign counter parts. This may be due to multiple reasons including food, cultural and geographical conditions. Indian people are known for more consumption of the species. Their food ingredients may be expected to be viding better health surveillance. The most notable finding was transformation of the accelerated phase and into the chronic phase in some patients. This follow up study supports the global view that the therapy with Imatinib mesylate may be continued unless resistance against it develops and it should be considered as the drug of first choice in CML.

Author(s): Amit K. Dutta, N. Ganesh, N K Sah, A. Vani